BTIG raised the firm’s price target on Akebia (AKBA) to $10 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Vafseo launch earlier this month in chronic kidney disease – CKD – with nearly 100% contract coverage as the only HIF stabilizer, only oral Tx option, and only non-ESA Tx option available in the U.S. to treat CKD anemia, the analyst tells investors in a research note. Market expectations are relatively low despite the wide open opportunity, and the stock trades at only a $450M enterprise value, indicating that the CKD opportunity is significantly discounted, the firm added.